Akhter J, Johnson L A, Gunasegaram A, Riordan S M, Morris D L
Cancer Research Laboratories, UNSW Department of Surgery St George Hospital, Sydney, NSW 2217, Australia.
Surgeon. 2007 Jun;5(3):155-64. doi: 10.1016/s1479-666x(07)80043-6.
Orthotopic liver transplantation (OLT) is standard clinical practice for patients with severe and end-stage chronic liver disease. However, the chronic shortage of donor livers and parallel growth of the transplant waiting list mean that a substantial proportion of patients die while waiting for a donor liver. Attempts to reduce the waiting list by use of split-liver and living-related live donor techniques have had some impact, but additional approaches to management are vital if the death rate is to be significantly reduced. Extensive laboratory research work and limited clinical trials have shown that hepatocyte transplantation may be useful in bridging some patients to OLT. A major limiting factor has been the shortage of mature functioning human hepatocytes, which are currently mostly obtained from livers rejected for OLT. This review examines potential hepatocyte sources, hepatocyte isolation methods and preservation protocols that have been successfully established, along with an overview of clinical results.
原位肝移植(OLT)是重症和终末期慢性肝病患者的标准临床治疗方法。然而,供肝长期短缺以及移植等待名单的同步增加意味着相当一部分患者在等待供肝的过程中死亡。采用劈离式肝移植和活体亲属供肝技术来减少等待名单的尝试已产生了一定影响,但如果要显著降低死亡率,其他管理方法至关重要。广泛的实验室研究工作和有限的临床试验表明,肝细胞移植可能有助于将一些患者过渡到OLT。一个主要限制因素是缺乏成熟且功能正常的人肝细胞,目前这些肝细胞大多来自因OLT而被拒收的肝脏。本综述探讨了已成功建立的潜在肝细胞来源、肝细胞分离方法和保存方案,以及临床结果概述。